It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Patient-derived xenografted (PDX) models were generated through the transplantation of primary acute lymphoblastic leukemia (ALL) cells into immunodeficient NSG mice. We observed that ALL cells from mouse bone marrow (BM) produced extracellular vesicles (EVs) with specific expression of inducible heat shock protein HSP70, which is commonly activated in cancer cells. Taking advantage of this specific expression, we designed a strategy to generate fluorescent HSP70-labeled ALL EVs and monitor the impact of these EVs on endogenous murine BM cells ex vivo and in vivo. We discovered that hematopoietic stem and progenitor cells (HSPC) were mainly targeted by ALL EVs, affecting their quiescence and maintenance in the murine BM environment. Investigations revealed that ALL EVs were enriched in cholesterol and other metabolites that contribute to promote the mitochondrial function in targeted HSPC. Furthermore, using CD34+ cells isolated from cord blood, we confirmed that ALL EVs can modify quiescence of human HSPC. In conclusion, we have discovered a new oncogenic mechanism illustrating how EVs produced by proliferative ALL cells can target and compromise a healthy hematopoiesis system during leukemia development.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 UMR1231, Inserm/Université Bourgogne Franche-Comté, Dijon, France (GRID:grid.493090.7) (ISNI:0000 0004 4910 6615); LipSTIC Labex, Dijon, France (GRID:grid.493090.7)
2 UMR1231, Inserm/Université Bourgogne Franche-Comté, Dijon, France (GRID:grid.493090.7) (ISNI:0000 0004 4910 6615)
3 UMR1231, Inserm/Université Bourgogne Franche-Comté, Dijon, France (GRID:grid.493090.7) (ISNI:0000 0004 4910 6615); Université Bourgogne Franche-Comté, Plateforme de Lipidomique Analytique, Dijon, France (GRID:grid.493090.7) (ISNI:0000 0004 4910 6615)
4 UMR1231, Inserm/Université Bourgogne Franche-Comté, Dijon, France (GRID:grid.493090.7) (ISNI:0000 0004 4910 6615); LipSTIC Labex, Dijon, France (GRID:grid.493090.7); Université Bourgogne Franche-Comté, Plateforme de Lipidomique Analytique, Dijon, France (GRID:grid.493090.7) (ISNI:0000 0004 4910 6615)
5 UMR1231, Inserm/Université Bourgogne Franche-Comté, Dijon, France (GRID:grid.493090.7) (ISNI:0000 0004 4910 6615); Hôpital Universitaire François Mitterrand, Laboratoire de Biochimie Spécialisée, Dijon, France (GRID:grid.493090.7)
6 UMR1231, Inserm/Université Bourgogne Franche-Comté, Dijon, France (GRID:grid.493090.7) (ISNI:0000 0004 4910 6615); LipSTIC Labex, Dijon, France (GRID:grid.493090.7); Centre Georges François Leclerc-Unicancer, Dijon, France (GRID:grid.418037.9) (ISNI:0000 0004 0641 1257)